246 related articles for article (PubMed ID: 27235858)
1. Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.
Hernandez L; Kim MK; Lyle LT; Bunch KP; House CD; Ning F; Noonan AM; Annunziata CM
Gynecol Oncol; 2016 Aug; 142(2):332-40. PubMed ID: 27235858
[TBL] [Abstract][Full Text] [Related]
2. In vivo tumor growth of high-grade serous ovarian cancer cell lines.
Mitra AK; Davis DA; Tomar S; Roy L; Gurler H; Xie J; Lantvit DD; Cardenas H; Fang F; Liu Y; Loughran E; Yang J; Sharon Stack M; Emerson RE; Cowden Dahl KD; V Barbolina M; Nephew KP; Matei D; Burdette JE
Gynecol Oncol; 2015 Aug; 138(2):372-7. PubMed ID: 26050922
[TBL] [Abstract][Full Text] [Related]
3. Beyond genomics: critical evaluation of cell line utility for ovarian cancer research.
Elias KM; Emori MM; Papp E; MacDuffie E; Konecny GE; Velculescu VE; Drapkin R
Gynecol Oncol; 2015 Oct; 139(1):97-103. PubMed ID: 26321251
[TBL] [Abstract][Full Text] [Related]
4. Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model.
Yu L; Wang Y; Yao Y; Li W; Lai Q; Li J; Zhou Y; Kang T; Xie Y; Wu Y; Chen X; Yi C; Gou L; Yang J
Int J Gynecol Cancer; 2014 Sep; 24(7):1158-64. PubMed ID: 24987913
[TBL] [Abstract][Full Text] [Related]
5. Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice.
De Haven Brandon A; Box G; Hallsworth A; Court W; Matthews N; Herodek B; Arteagabeitia AB; Valenti M; Kirkin V
Sci Rep; 2020 Jul; 10(1):10799. PubMed ID: 32612269
[TBL] [Abstract][Full Text] [Related]
6. Patient-Derived Xenograft Models for Ovarian Cancer.
Tran TM; Ho GY; Chu S
Methods Mol Biol; 2024; 2806():187-196. PubMed ID: 38676803
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of human ovarian cancer cells.
Liu Y; Zheng D; Liu M; Bai J; Zhou X; Gong B; Lü J; Zhang Y; Huang H; Luo W; Huang G
Tumour Biol; 2015 Sep; 36(10):7997-8006. PubMed ID: 25967456
[TBL] [Abstract][Full Text] [Related]
8. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
9. [*OPCML gene transferred by recombinant lentiviruses in vitro and its inhibition to ovarian cancer cells].
Yao DS; Li L; Garson K; Vanderhyden BC
Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):333-8. PubMed ID: 16762191
[TBL] [Abstract][Full Text] [Related]
10. Use of nude mouse xenografts as preclinical drug screens. Further studies on in vitro growth of xenograft tumor colony-forming cells.
Taetle R; Honeysett JM; Rosen F; Shoemaker R
Cancer; 1986 Nov; 58(9):1969-78. PubMed ID: 3756816
[TBL] [Abstract][Full Text] [Related]
11. Effects of Per2 overexpression on growth inhibition and metastasis, and on MTA1, nm23-H1 and the autophagy-associated PI3K/PKB signaling pathway in nude mice xenograft models of ovarian cancer.
Wang Z; Li L; Wang Y
Mol Med Rep; 2016 Jun; 13(6):4561-8. PubMed ID: 27082164
[TBL] [Abstract][Full Text] [Related]
12. METCAM/MUC18 is a novel tumor and metastasis suppressor for the human ovarian cancer SKOV3 cells.
Wu GJ; Zeng GF
BMC Cancer; 2016 Feb; 16():136. PubMed ID: 26906545
[TBL] [Abstract][Full Text] [Related]
13. Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer.
Isayeva T; Ren C; Ponnazhagan S
Clin Cancer Res; 2005 Feb; 11(3):1342-7. PubMed ID: 15709207
[TBL] [Abstract][Full Text] [Related]
14. Generation of stable PDX derived cell lines using conditional reprogramming.
Borodovsky A; McQuiston TJ; Stetson D; Ahmed A; Whitston D; Zhang J; Grondine M; Lawson D; Challberg SS; Zinda M; Pollok BA; Dougherty BA; D'Cruz CM
Mol Cancer; 2017 Dec; 16(1):177. PubMed ID: 29212548
[TBL] [Abstract][Full Text] [Related]
15. IL-13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer.
Fujisawa T; Joshi BH; Puri RK
Int J Cancer; 2012 Jul; 131(2):344-56. PubMed ID: 21858811
[TBL] [Abstract][Full Text] [Related]
16. [Effect and mechanism of gene therapy of lentivirus mediated RhoA shRNA on ovarian cancer xenograft in vivo].
Jiang WY; Kang JL; Wang XX; Yang WJ; Nie ML; Zhou C
Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):778-83. PubMed ID: 24406137
[TBL] [Abstract][Full Text] [Related]
17. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
Wang D; Pham NA; Tong J; Sakashita S; Allo G; Kim L; Yanagawa N; Raghavan V; Wei Y; To C; Trinh QM; Starmans MH; Chan-Seng-Yue MA; Chadwick D; Li L; Zhu CQ; Liu N; Li M; Lee S; Ignatchenko V; Strumpf D; Taylor P; Moghal N; Liu G; Boutros PC; Kislinger T; Pintilie M; Jurisica I; Shepherd FA; McPherson JD; Muthuswamy L; Moran MF; Tsao MS
Int J Cancer; 2017 Feb; 140(3):662-673. PubMed ID: 27750381
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibition of ovarian tumor-initiating cells by niclosamide.
Yo YT; Lin YW; Wang YC; Balch C; Huang RL; Chan MW; Sytwu HK; Chen CK; Chang CC; Nephew KP; Huang T; Yu MH; Lai HC
Mol Cancer Ther; 2012 Aug; 11(8):1703-12. PubMed ID: 22576131
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of a cell line (HCH-1) originating from a human clear cell carcinoma of the ovary.
Yamada T; Hattori K; Satomi H; Okazaki T; Mori H; Hirose Y
J Ovarian Res; 2016 Jun; 9(1):32. PubMed ID: 27259990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
